دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
A Plea for Economically Sustainable Evidence-based Guidelines
AlbertoMartiniaNicolasMottetbFrancescoMontorsicAndreaNecchidMaria J.RibaleBernardMalavauda
Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3–5) and Negative Initial Biopsy. A Mini Systematic Review
NikolaosGrivasab†MichaelLardasc†Estefania LinaresEspinósdThomas B.LameOlivierRouvierefNicolasMottetgRoderick C.N.van den BerghhMembers of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Prostate Cancer Guidelines Panel‡
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours
HolgerMocha1Mahul B.AminbcDaniel M.BerneydeEva M.CompératfAnthony J.Gillgh1ArndtHartmanniSantoshMenonjMaria R.RaspollinikMark A.RubinlJohn R.Srigleym1PuayHoon Tann1Satish K.TickoooToyonoriTsuzukip1SamraTurajlicqIanCreer2George J.Nettos
The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
George J.NettoaMahul B.AminbcDaniel M.BerneydeEva M.CompératfAnthony J.Gillghi1ArndtHartmannjSantoshMenonkMaria R.RaspollinilMark A.RubinmJohn R.Srigleyn1PuayHoon Tano1Satish K.TickoopToyonoriTsuzukiq1SamraTurajlicrIanCrees2HolgerMocht1
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity
RodolfoMontironiaAlessiaCimadamoreb
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)
Ting MartinMaaFang-IChuaHowardSandlerbFelix Y.FengcJason A.EfstathioudChristopher U.JoneseMackRoach3rdfSeth A.RosenthaleThomasPisanskygJeff M.MichalskihMichelBollaiTheo M.de ReijkejPhilippeMaingonkAnoukNevenlJamesDenhammAllisonSteiglermDavidJosephnAbdenourNabido…Amar U.Kishana
The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis
DavidChangabPierreBlanchardcShankarSivaab
18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial
KathiaDe ManaNickVan LaekenaVanessaSchelfhoutaWolfgang P.FendlerbBiekeLambertcdeKenKersemansaSarahPironfNicolaasLumengKarelDecaesteckergValérieFonteynehLoukeDelrueiFilipDe VosfPietOstej
18F-PSMA-11 as an Attractive 68Ga-PSMA-11 Alternative for Prostate Cancer Imaging
Pim J.van LeeuwenaLouiseEmmettb
Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial
Simon J.CrabbaGarethGriffithsaDeniseDunkleyaNicholaDownsaMaryEllisaMikeRadfordaMichelleLightaJoshNortheyaAmyWhiteheadaSamWildingaAlison J.BirtlebVincentKhoocRobert J.Jonesd
A Path to Precision Medicine in Prostate Cancer: Learning from “Negative� Trials of Targeted Therapies
Tanya B.DorffaAlicia K.Morgansb
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer
Ben-Maxde Ruiterab1Jons W.van Hattumab1DjoeriLipmancTheo M.de ReijkeabR. Jeroen A.van MoorselaarbdErik J.van GennepeA.H.Maartje PietbfMilaDonkergTomvan der HullehJensVoortmanbiJorg R.OddensabMaarten C.C.M.HulshofbjAdriaan D.Binsbk
Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder Cancer
PoojaGhataliaElizabeth R.Plimack
Epidemiology of Renal Cell Carcinoma: 2022 Update
LauraBukavinaabKarimBensalahcFreddieBraydMariaCarloeBenChallacombefJose A.KaramgWassimKassoufhThomasMitchelliRodolfoMontironijTimO'BrienfValeriaPanebiancokGhislaineScelolBrianShuchmHeinvan PoppelnChristopher D.BlosseroSarah P.Psutkao
Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre
PengXua1ChunxiaoChena1BinshenChenaEnguangBiabWeiDuaNingJiangaZheLiuaHekuiLancManmingCaodYazhenLiuaJingwenHuangaHaiyanShenaCunrongLiuaChunxiaoLiuaAbaiXua
Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique
Jihad H.KaoukaEthan L.FergusonaAlp TunaBeksacaMahmoud AbouZeinabaAaronKavianiaChristopherWeightaSamuelHaywoodaMohamedEltemamyaAndreiPuryskobJesse K.McKenneycEricKleina
Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging–detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score
MaxPetersaDavidEldred-EvansbPietKurveraUgo GiovanniFalagariocMartin J.ConnorbTaimur T.ShahbJoost J.C.VerhoeffaPekkaTaimendHannu J.AroneneJuhaKnaapilafIleanaMontoya PerezgOttoEttalafArmandoStabilehGiorgioGandagliahNicolaFossatihAlbertoMartinihVitoCucchiarahAlbertoBrigantih…Hashim U.Ahmedb
Re: Fragmentation of Stones by Burst Wave Lithotripsy in the First 19 Humans
HeikoYangMarshallStoller
Re: Development and Validation of the Metric-based Assessment of a Robotic Dissection Task on an Avian Model
CarolineJamaerAnne-FrançoiseSpinoit
Re: Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer: The PANDA Challenge
ProkarDasgupta
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial
ClaudiaKeschBoris A.Hadaschik
Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer
AntoniVilasecaMaria J.Ribal
Re: Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study
ChiaraLonatiNazarenoSuardi
Re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879–86 AR-V7 is Rare in Hormone-sensitive Prostate Cancer: AR-V7 is Rare in Hormone-sensitive Prostate Cancer
Adam G.SowalskyaStephen R.PlymatebcMichael C.HaffnerbdJohann S.de BonoefAdamSharpef
Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp’s Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879–86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer
HengLiabYucongZhangcHuaXude
Reply to Andreas Skolarikos’s Words of Wisdom re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial. Eur Urol. In press
James W.F.CattoabcPramitKhetrapalcGarethAmblerdNorman R.WilliamseChrisBrew-GravesfJohn D.Kellyc
Reply to Yuxuan Song, Yiqing Du, and Tao Xu’s Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466–73
Filipe L.F.CarvalhoaMatthewMossanenaEliezer M.Van AllencKent W.Mouwb
Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. 18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. Eur Urol. 2022;82:501–509
FrancescoMontorsiGiorgioGandagliaDanieleRobestiFedericoDehòAlbertoBriganti
Re: Sabrina H. Rossi, Grant D. Stewart. Re: Clinical Validation of a Targeted Methylation-based Multi-cancer Early Detection Test Using an Independent Validation Set. Eur Urol. 2022;82:442–443
Eric A.Klein
Re: Logan G. Briggs, Chanan Reitblat, Paul A. Bain, et al. Prehabilitation Exercise Before Urologic Cancer Surgery: A Systematic and Interdisciplinary Review. Eur Urol 2022;81:157–67: Recommendations for Experiments on Prehabilitation Exercise Programs for Health Optimization Before Cancer Surgeries
AndréPontes-Silvaab
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol 2022;81:576–85
MikeWenzelFelix K-H.ChunAndreasBecker
Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.031
FrancescoMontorsiaCarlo AndreaBraviabcGiorgioGandagliaaAlexandreMottriebcAlbertoBrigantia
Re: Christian Fuglesang S. Jensen, Dana A. Ohl, Mikkel Fode, et al. Microdissection Testicular Sperm Extraction Versus Multiple Needle-pass Percutaneous Testicular Sperm Aspiration in Men with Nonobstructive Azoospermia: A Randomized Clinical Trial. Eur Urol. 2022;82:377–384
BoLia†ChenDuana†XiangyangYaocXiaoliangWuaHuaXubc
Reply to Bo Li, Chen Duan, Xiangyang Yao, Xiaoliang Wu, and Hua Xu’s Letter to the Editor re: Christian Fuglesang S. Jensen, Dana A. Ohl, Mikkel Fode, et al. Microdissection Testicular Sperm Extraction Versus Multiple Needle-pass Percutaneous Testicular Sperm Aspiration in Men with Nonobstructive Azoospermia: A Randomized Clinical Trial. Eur Urol. 2022;82:377–384
Christian Fuglesang S.JensenMikkelFodeJensSønksen
Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma� [Eur Urol 2022]
MuhammadAliabJenniferMooicNathanLawrentschukdefRana R.McKaygRaquibulHannanhSimon S.LoiWilliam A.HalljShankarSivaab
